TG and neoplasm: Results: Patients with the BRAF V600E mutation were older, presented with advanced stages, and had higher Tg and calcitonin levels, correlating with tumor progression (e.g., Tg: 30.5 ng/mL in stage I vs. 62.0 ng/mL in stage IV).